Actively Recruiting

Phase 3
Age: 20Years - 50Years
MALE
ID06274333

The Effect of Adding Dexmedetomidine or Tramadol to Paracetamol to Reduce Catheter Related Bladder Discomfort: A Randomized, Triple-Blind Clinical Trial

Led by Al-Azhar University · Updated on 2026-01-06

60

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

Sponsors

A

Al-Azhar University

Lead Sponsor

B

Benha University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying catheter-related bladder discomfort (CRBD) that can occur after urinary catheter insertion during surgical procedures, particularly urinary interventions. This clinical trial evaluates the effects of adding dexmedetomidine or tramadol to paracetamol in managing CRBD and postoperative pain. The study is a randomized, triple-blind, phase 3 trial aimed at understanding how these drug combinations may reduce discomfort after surgery. Participants will be divided into two groups. One group will receive dexmedetomidine at 0.5 micrograms per kilogram combined with paracetamol at 10 milligrams per kilogram, while the other group will receive tramadol at 1 milligram per kilogram plus paracetamol at the same dose. These treatments will be administered during the surgical period to assess their effects on bladder discomfort and pain. During the study, researchers will monitor participants for 24 hours after surgery to measure the incidence of CRBD as the primary outcome. Secondary outcomes include evaluating postoperative pain, the need for additional pain medication (meperidine), and satisfaction levels of both patients and surgeons. The study involves adult male patients aged 20 to 50 years undergoing percutaneous nephrolithotomy (PCNL).

CONDITIONS

Brief Title

Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort

Who Can Participate

Age: 20Years - 50Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age from 20 to 50 years
  • Male patients
  • Classified as ASA I or II (healthy or mild systemic disease)
  • Undergoing percutaneous nephrolithotomy (PCNL) surgery
Not Eligible

You will not qualify if you...

  • History of psychotic illnesses
  • Current opioid use
  • Bladder obstruction
  • Benign prostatic hyperplasia
  • Overactive bladder defined as urinating 3 or more times at night or 8 or more times within 24 hours

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 24 hours postoperatively

Participants receive either dexmedetomidine with paracetamol or tramadol with paracetamol to reduce catheter-related bladder discomfort during surgery.

1 treatment and observation period

Trial Site Locations

Total: 1 location

1

Neveen Kohaf

Cairo, Cairo Governorate, Egypt, 11865

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here